HUMULIN 70/30 PEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HUMULIN 70/30 PEN (HUMULIN 70/30 PEN).
Insulin lispro and insulin lispro protamine suspension. Insulin lispro lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, facilitating glucose uptake, and inhibiting hepatic glucose production. Insulin lispro protamine provides intermediate-acting basal coverage.
| Metabolism | Insulin lispro is primarily metabolized by hepatic and renal insulin-degrading enzymes (IDE). |
| Excretion | Insulin is primarily eliminated via renal metabolism and excretion; approximately 30-80% is cleared by the kidneys, with the remainder undergoing hepatic metabolism. Biliary/fecal excretion is negligible (<1%). |
| Half-life | The terminal elimination half-life of insulin in Humulin 70/30 is approximately 1.5 hours for the regular insulin component and 4-6 hours for the NPH component due to protamine suspension, resulting in a prolonged duration of action. |
| Protein binding | Insulin is minimally bound to plasma proteins; binding to albumin is less than 10%. Specific binding proteins are not clinically significant. |
| Volume of Distribution | Volume of distribution for insulin is approximately 0.2-0.4 L/kg, indicating distribution primarily into extracellular fluid. |
| Bioavailability | Subcutaneous administration: bioavailability is 100% for the regular human insulin component; the NPH component is fully absorbed but with prolonged release due to protamine suspension. |
| Onset of Action | Subcutaneous administration: onset of action is 30-60 minutes for the regular insulin component. |
| Duration of Action | Subcutaneous administration: duration of action is 12-16 hours for the NPH component; the biphasic profile provides both prandial and basal coverage. |
Subcutaneous injection, individualized based on metabolic needs and blood glucose monitoring; typical starting dose for type 1 diabetes: 0.5 to 0.6 units/kg/day in divided doses (usually twice daily with 70% intermediate-acting NPH and 30% regular insulin); for type 2 diabetes: 0.2 units/kg/day initially, adjusted per glycemic response.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <30 mL/min: reduce dose by 25-50% and monitor glucose closely; dialysis patients: avoid due to unpredictable absorption; severe renal impairment: intensive glucose monitoring required. |
| Liver impairment | Child-Pugh Class B or C: consider dose reduction by 25-50% due to impaired gluconeogenesis and altered insulin metabolism; monitor for hypoglycemia. |
| Pediatric use | Weight-based dosing: 0.5-1 unit/kg/day total insulin (for type 1 diabetes) divided into two daily doses; 70% NPH and 30% regular; adjust based on blood glucose trends; not recommended for children <6 years due to fixed ratio. |
| Geriatric use | Start at lower doses (e.g., 0.2-0.3 units/kg/day) due to renal impairment and increased hypoglycemia risk; avoid tight glycemic control if at risk for falls or cognitive impairment. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HUMULIN 70/30 PEN (HUMULIN 70/30 PEN).
| Breastfeeding | Insulin is endogenous in breast milk; exogenous insulin levels are negligible. M/P ratio not established. Compatible with breastfeeding; may require dosage adjustment. |
| Teratogenic Risk | Insulin does not cross the placenta in significant amounts; no known teratogenic risk. Poor glycemic control increases congenital malformation risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to insulin lispro or any component of the formulation","During episodes of hypoglycemia"]
| Precautions | ["Hypoglycemia is the most common adverse effect","Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control and predispose to hypoglycemia or hyperglycemia","Needle sharing poses risk of hepatitis and other infections","Patients should be advised to rotate injection sites to reduce risk of lipodystrophy","Use with caution in patients with renal or hepatic impairment","May cause hypokalemia; monitor potassium levels in patients at risk"] |
Loading safety data…
| Monitor blood glucose, HbA1c, and fetal growth via ultrasound. Assess for macrosomia, polyhydramnios, and neonatal hypoglycemia. |
| Fertility Effects | Uncontrolled diabetes can impair fertility; glycemic control with insulin improves outcomes. Direct effect on fertility unlikely. |